Orexo converts vipoglanstat royalties into Gesynta stake

20 January 2025

Swedish pharmaceutical company Orexo (STO: ORX) has converted its rights to future transaction proceeds and royalties from vipoglanstat into shares in Gesynta Pharma.

The move follows Gesynta’s recent capital raise, with Orexo’s shares valued at 19.2 million kronor ($1.84 million). The development reflects Orexo’s ongoing efforts to bolster its financial results and equity position.

Orexo originally sold the rights to vipoglanstat to Gesynta in 2017 under a purchase agreement, entitling Orexo to a share of future revenues and royalties from the drug.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical